Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Portfolio Pulse from Vandana Singh
Arcturus Therapeutics and CSL Limited's COVID-19 vaccine, ARCT-154, demonstrated superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, even at lower doses. The vaccine showed better antibody responses against various COVID-19 variants, including Omicron, over a year. ARCT-2301, another vaccine from the same platform, also outperformed Comirnaty in inducing neutralizing antibodies.
September 30, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's Comirnaty was outperformed by Arcturus and CSL's ARCT-154 in a Phase 3 study, which may impact Pfizer's competitive position in the COVID-19 vaccine market.
The Phase 3 study results showing ARCT-154's superior performance over Comirnaty could negatively impact Pfizer's competitive position in the COVID-19 vaccine market.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
Arcturus Therapeutics' COVID-19 vaccine, ARCT-154, showed superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, leading to a 4.70% increase in stock price.
The positive Phase 3 study results for ARCT-154, showing superior immunogenicity over Pfizer's Comirnaty, are likely to boost investor confidence in Arcturus Therapeutics, as reflected in the 4.70% stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
CSL Limited, in partnership with Arcturus, announced that their COVID-19 vaccine, ARCT-154, outperformed Pfizer's Comirnaty in a Phase 3 study, potentially enhancing CSL's market position.
CSL Limited's involvement in the successful development of ARCT-154, which outperformed Pfizer's Comirnaty, could strengthen its market position and investor sentiment.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 80